Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Paratek Pharmaceuticals, Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 101 staff and has a trailing 12-month revenue of around USD$39.9 million.
|Latest market close||USD$6.21|
|52-week range||USD$2.5 - USD$6.72|
|50-day moving average||USD$5.375|
|200-day moving average||USD$4.9523|
|Wall St. target price||USD$17.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.845|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.49%|
|1 month (2020-10-23)||25.45%|
|3 months (2020-08-24)||32.41%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-23)||N/A|
|2 years (2018-11-23)||-13.99%|
|3 years (2017-11-24)||-69.63%|
|5 years (2015-11-24)||-67.42%|
|Revenue TTM||USD$39.9 million|
|Gross profit TTM||USD$-26,494,000|
|Return on assets TTM||-22.47%|
|Return on equity TTM||0%|
|Market capitalisation||USD$276.6 million|
TTM: trailing 12 months
There are currently 3.8 million Paratek Pharmaceuticals shares held short by investors – that's known as Paratek Pharmaceuticals's "short interest". This figure is 5.5% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Paratek Pharmaceuticals shares can be evaluated.
Paratek Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Paratek Pharmaceuticals shares currently shorted divided by the average quantity of Paratek Pharmaceuticals shares traded daily (recently around 327606.25). Paratek Pharmaceuticals's SIR currently stands at 11.68. In other words for every 100,000 Paratek Pharmaceuticals shares traded daily on the market, roughly 11680 shares are currently held short.
However Paratek Pharmaceuticals's short interest can also be evaluated against the total number of Paratek Pharmaceuticals shares, or, against the total number of tradable Paratek Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Paratek Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Paratek Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0878% of the tradable shares (for every 100,000 tradable Paratek Pharmaceuticals shares, roughly 88 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Paratek Pharmaceuticals.
Find out more about how you can short Paratek Pharmaceuticals stock.
We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.
Paratek Pharmaceuticals's shares were split on a 1:12 basis on 31 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.
Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $2.5 up to $6.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.487. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.